Medical Devices South Africa

South Africa Pharmacogenomic Testing Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

South Africa Pharmacogenomic Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

South Africa · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $18.5 Mn Placeholder estimate
Estimate 2025 $20.7 Mn 0.7% of the global market
Projected 2034 $55.5 Mn 168.5% Adds $34.8 Mn over 9 forecast years
CAGR 2025–2034 11.6% Faster than 63% of 173 Medical Devices markets here
Key players 5
  • South Africa is 0.66% of the global market.
  • In Africa, the largest is South Africa (this report) at $20.7 Mn.
  • Fastest growing: South Africa (this report) at 11.6% a year.
  • South Africa ranks 1st of 3 by size in Africa.

Market size projection

South Africa

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$34.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Pharmacogenomic Testing Market market size by year, South Africa
YearMarket sizeChange that yearSince 2025
2024 (estimate) $18.5 Mn — —
2025 (base) $20.7 Mn +$2.1 Mn —
2026 (forecast) $23.1 Mn +$2.4 Mn +11.6%
2027 (forecast) $25.7 Mn +$2.7 Mn +24.5%
2028 (forecast) $28.7 Mn +$3.0 Mn +39%
2029 (forecast) $32.1 Mn +$3.3 Mn +55.1%
2030 (forecast) $35.8 Mn +$3.7 Mn +73.1%
2031 (forecast) $39.9 Mn +$4.2 Mn +93.2%
2032 (forecast) $44.6 Mn +$4.6 Mn +115.6%
2033 (forecast) $49.7 Mn +$5.2 Mn +140.6%
2034 (forecast) $55.5 Mn +$5.8 Mn +168.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

South Africa Pharmacogenomic Testing Market Analysis at a glance
Market size, 2025$20.7 Mn placeholder estimate
Forecast, 2034$55.5 Mn placeholder estimate
Growth (CAGR), 2025–203411.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, application and end user (see all)
Key playersMyriad Genetics, Inc., OneOme, Genomind, Thermo Fisher Scientific Inc., RPRD Diagnostics (see all)
Regulator in South AfricaSAHPRASource: South African Health Products Regulatory Authority. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The South Africa Pharmacogenomic Testing Market Analysis Executive Summary

Pharmacogenomic testing checks a person's genes to predict how they will respond to medicines, helping choose the right drug and dose.

Key segments of the pharmacogenomic Testing market include test (Multi-Gene Panels and Single-Gene Tests) and application (Psychiatry, Cardiology and Oncology).

Bar chart: South Africa Pharmacogenomic Testing market size, 2024–2034, placeholder estimates. $18.5 Mn in 2024, $20.7 Mn in 2025 and $55.5 Mn in 2034, 11.6% CAGR.
South Africa Pharmacogenomic Testing market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

South Africa Pharmacogenomic Testing Market Dynamics

Market Growth Drivers

The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the pharmacogenomic Testing market.

Opportunity

Routine use of genomics in screening, pharmacy and primary care gives the pharmacogenomic Testing market large room to grow.

Market Restraints

Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the pharmacogenomic Testing market.

Competitive Landscape for Pharmacogenomic Testing Market in South Africa

The pharmacogenomic Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Pharmacogenomic Testing Market in South Africa

Pharmacogenomic Testing in South Africa: rules and payment

The South African Health Products Regulatory Authority (SAHPRA) regulates medical devices, starting with licences for the companies that make, import and sell them.⁠[1] Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone.⁠[2]

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in South Africa.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Pharmacogenomic Testing right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Pharmacogenomic Testing in context

South Africa compared

  • Health spending per person: 537 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 17 countries we cover in Africa.[1]
  • Doctors: 0.79 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 17 countries we cover in Africa.[2]
  • People aged 65 and over: 6.9% of people (2025). World: 10.4% of people (2025). 2nd highest of the 17 countries we cover in Africa.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Pharmacogenomic Testing market in South Africa?
Placeholder estimate: about $20.7 Mn in 2025, rising to about $55.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pharmacogenomic Testing market in South Africa growing?
Placeholder estimate: about 11.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pharmacogenomic Testing market report cover?
The report splits the market by test (Multi-Gene Panels, Single-Gene Tests), application (Psychiatry, Cardiology, Oncology, Pain Management) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Pharmacogenomic Testing market?
Key players include Myriad Genetics, Inc., OneOme, Genomind, Thermo Fisher Scientific Inc. and RPRD Diagnostics.
What is driving the Pharmacogenomic Testing market?
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the pharmacogenomic Testing market.
Who regulates Pharmacogenomic Testing in South Africa?
The South African Health Products Regulatory Authority (SAHPRA) regulates medical devices, starting with licences for the companies that make, import and sell them. Source: South African Health Products Regulatory Authority. Checked 14 Nov 2026.
How is healthcare paid for in South Africa?
Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone. Source: National Department of Health. Checked 14 Nov 2026.
How much research is published on Pharmacogenomic Testing?
PubMed lists 369 papers on Pharmacogenomic Testing added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in South Africa

See all

Related on genomics and diagnostics and lab testing

See the topic